Barbara Ryan
Barbara Ryan
Barbara Ryan Colemanis a fictional character from the American CBS soap opera As the World Turns. In the early 1970s, Barbara was played by a succession of actresses, but the actress most associated with the role is Colleen Zenk, who played her since September 1, 1978. Better known as simply Barbara Ryan she is portrayed as a heroine who experienced many tragedies, mostly at the hands of her controlling ex-husband, the villainous James Stenbeck...
altogether cash certainty clearly company disregard generic given greater industry litigation settle translate tremendous unlikely
Pfizer clearly is a company with tremendous disregard for the generic drug industry and is not given to settling. But it is not altogether unlikely that Pfizer could settle its litigation. If Pfizer could translate some of its cash hoards into greater certainty on this litigation ... I think they would do that.
activity although clear economic economies force fourth full fully impact katrina known local projected rita scope slow third
Although the full force of the impact of Hurricanes Katrina and Rita will not be fully known for some time, it is clear that the scope of the devastation is unprecedented for the local economies and is projected to slow U.S. economic activity in the third and fourth quarters.
clear detail heard humbled loud management recognize team
You're going to see a much more transparent and humbled management team with a lot more detail and granularity on a whole lot of issues, which is not characteristic of Pfizer historically. They have heard their shareholders loud and clear and recognize that they need to be transparent and more visible.
clear company growth vehicle view
The only company which is a clear growth vehicle in our view is Schering-Plough.
clear evidence joint momentum positive provide recent results turnaround
Recent results provide clear evidence of the turnaround at Schering-Plough and the positive momentum of the cholesterol joint venture.
based cost earnings expect recovery year
Bristol-Myers earnings will be down this year but then we expect to see a recovery based on the introduction of new drugs and cost cuts.
benefit lose money
Merck and Pfizer would probably lose money from a moratorium. They have portfolios that would benefit from DTC advertising.
benefit lose money
Merck and Pfizer would probably lose money from a moratorium, ... They have portfolios that would benefit from DTC advertising.
betting companies innovative pipeline worse
Lilly has been more innovative than most other companies but done worse at execution. There's betting on a pipeline that hasn't panned out in the past.
change higher people point
It doesn't change much. But it does point people to the higher end of the range.
fold months street telling tent three waiting wall
Three months ago, Wall Street was telling Pfizer to fold up its tent and go home. Now some of the things we've been waiting for are coming.
below brands generally key sales
Fourth-quarter 2005 sales of key brands were generally below our forecasts.
appears economics far merger neutral quite revenue short somewhat stock trend
So far the integration appears to be going well. The economics of the merger are going to be quite strong. We're somewhat disappointed in the near-term revenue trend and are neutral on the stock in the short run.
behind cases modest positive
modest positive for the stock, modest because they have 6,000 cases behind this one.